Adverse reactions of dabigatran etexilate capsules (Pradaxa)

Dabigatran etexilate capsules (Pradaxa) is a drug used for anticoagulant therapy, used to prevent and treat thrombosis-related diseases, such as non-valvular atrial fibrillation, deep vein thrombosis and pulmonary embolism. Although it is very effective at reducing the risk of blood clots, like all medications, dabigatran etexilate may cause some adverse reactions. Here are some possible adverse reactions and detailed descriptions:

1. Bleeding risk:

Gastrointestinal bleeding: One of the most common adverse reactions during the use of dabigatran etexilate capsules is gastrointestinal bleeding, including gastric ulcers and bleeding. Patients may experience symptoms such as melena, vomiting blood, and abdominal pain.

Urinary tract bleeding: May cause blood stains in the urine, accompanied by symptoms such as frequent urination and urgency.

Subcutaneous tissue bleeding: May cause congestion, ecchymosis, or bruising.

2. Gastrointestinal discomfort:

The use of dabigatran etexilate capsules may cause some gastrointestinal discomfort, including nausea, vomiting, diarrhea, etc. These symptoms are usually mild, but may be more severe in some patients.

3. Abnormal liver function:

Dabigatran etexilate capsules may cause liver function abnormalities during use, manifested as elevated transaminases. Therefore, the patient's liver function needs to be monitored regularly during use.

4. Anemia:

Long-term use of dabigatran etexilate capsules may cause anemia. Patients may feel tired, weak, and have symptoms such as heart palpitations.

5. Abnormal kidney function:

The excretion of dabigatran etexilate capsules is closely related to the kidneys, so dosage adjustments may be required in patients with impaired renal function to prevent excessive anticoagulation leading to an increased risk of bleeding.

6. Allergic reaction:

A small number of patients may have allergic reactions to the ingredients in dabigatran etexilate capsules, manifesting as rash, urticaria, shortness of breath and other symptoms.

7. Intestinal obstruction:

Dabigatran etexilate capsules may cause the risk of intestinal obstruction during use, especially when used before and after surgery. Patients should inform their doctor if they have any relevant medical history before use.

It needs to be emphasized that patients should carefully read the drug instructions provided by their doctor before using dabigatran etexilate capsules and receive regular medical monitoring. If patients experience any discomfort or symptoms of suspected adverse drug reactions during medication, they should consult a doctor in time. Physicians will evaluate the risks and benefits on a patient-specific basis and may adjust dosage or take other measures to ensure the safety and effectiveness of the treatment. You should not adjust the dosage or stop using the medicine on your own, but should do so under the guidance of a doctor.

Dabigatran etexilate capsules have been launched in China and have been included in medical insurance. Patients can purchase them domestically. Please consult the local hospital pharmacy for specific prices. The main foreign drug is the original drug of dabigatran etexilate capsules. The cheaper one is the Turkish version of the original drug from Germany. The price of 110mg*60 capsules is about three to four hundred, and the ingredients and efficacy are consistent with the original drug on the domestic market.